<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although Epstein-Barr virus (EBV) was discovered in cultured Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cells, its exact role remains unclear </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0001799'>Viral</z:mp> genome is found in 95-98% of endemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and 15-20% of non-endemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Children destined to develop <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> in Africa show elevated titres of <z:mp ids='MP_0001799'>viral</z:mp> capsid antibodies one to two years preceding emergence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>A multistep process follows early <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> during early childhood </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0002721'>Immune deficiency</z:hpo> probably permits continuation of the <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, with smouldering polyclonal B-cell proliferation proceeding </plain></SENT>
<SENT sid="5" pm="."><plain>Final steps in the pathogenesis consist of cytogenetic and molecular conversion to monoclonal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Reciprocal chromosomal translocations involve breakpoints containing c-myc, heavy- and light-chain Ig loci </plain></SENT>
<SENT sid="7" pm="."><plain>Activation of oncogenes, c-myc and B-lym, may be essential in the molecular pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>A spectrum of EBV-induced pathological entities is found in individuals with <z:hpo ids='HP_0001417'>X-linked</z:hpo> lymphoproliferative and acquired <z:hpo ids='HP_0002721'>immune deficiency</z:hpo> syndromes </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0002665'>Lymphoma</z:hpo> identical to endemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> occurs in these immune-deficient patients </plain></SENT>
<SENT sid="10" pm="."><plain>Non-endemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> is possibly due to immune defects, initiators and promoters of B-cell proliferation, which may not be identical to factors in endemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>; however, cytogenetic events and activation of oncogenes may be pathways of both endemic and non-endemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
</text></document>